Stock PROK PROKIDNEY CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Company ProKidney Corp.

Equities

PROK

KYG7S53R1049

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-05-14 pm EDT 		5-day change 1st Jan Change
3.92 USD -4.85% Intraday chart for ProKidney Corp. -4.85% +120.22%
May. 10 ProKidney Q1 Loss Unchanged From Year Earlier MT
May. 10 ProKidney Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Business Summary

ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).

Number of employees: 163

Managers

Managers TitleAgeSince
Bruce Culleton CEO
 Chief Executive Officer 57 23-07-16
James Coulston DFI
 Director of Finance/CFO 48 21-12-31
Joseph Stavas CTO
 Chief Tech/Sci/R&D Officer 69 19-09-30
Nikhil Pereira-Kamath PRN
 Corporate Officer/Principal - -
Darin Weber LAW
 General Counsel 56 20-08-31
Todd Girolamo LAW
 General Counsel 59 22-02-28

Members of the board

Members of the board TitleAgeSince
Bill Doyle BRD
 Director/Board Member 61 21-12-31
Brian Pereira BRD
 Director/Board Member 65 21-12-31
John Maraganore BRD
 Director/Board Member 60 22-08-10
Alan Lotvin BRD
 Director/Board Member 62 21-12-31
Pablo Legorreta CHM
 Chairman 60 21-12-31
Uma Sinha BRD
 Director/Board Member 67 -
Jennifer Fox BRD
 Director/Board Member 53 22-07-10
José Ignacio Jiménez Santos BRD
 Director/Board Member 49 -
Bruce Culleton CEO
 Chief Executive Officer 57 23-07-16

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 63,923,230 59,621,607 ( 93.27 %) 0 93.27 %

Shareholders

NameEquities%Valuation
Morgan Stanley Investment Management, Inc.
16.76 %
10,326,678 16.76 % 28 M $
GBM Administradora de Activos, SA de CV SOSI
9.546 %
5,882,500 9.546 % 16 M $
BANCO INVEX, S.A., INSTITUCION DE BANCA MULTIPLE, INVEX GRUPO FINANCIERO
8.114 %
5,000,000 8.114 % 14 M $
Jupiter Can LP
8.114 %
5,000,000 8.114 % 14 M $
Ihci Investment LP
8.074 %
4,975,125 8.074 % 13 M $
Suvretta Capital Management LLC
6.277 %
3,867,847 6.277 % 10 M $
Chamath Palihapitiya
4.868 %
3,000,000 4.868 % 8 M $
BlackRock Advisors LLC
4.240 %
2,613,003 4.240 % 7 M $
Bleichroeder LP
3.246 %
2,000,000 3.246 % 5 M $
Vanguard Fiduciary Trust Co.
2.942 %
1,813,079 2.942 % 5 M $
NameEquities%Valuation
Pablo Legorreta
51.92 %
88,639,961 51.92 % 240 M $
Helu Slim
36.97 %
63,118,645 36.97 % 171 M $
Tim Bertram
2.075 %
3,542,669 2.075 % 10 M $
Bill Doyle
0.8230 %
1,405,088 0.8230 % 4 M $
Brian Pereira
0.8230 %
1,405,088 0.8230 % 4 M $
Alan Lotvin
0.8230 %
1,405,088 0.8230 % 4 M $
Deepak Jain
0.6971 %
1,190,056 0.6971 % 3 M $
John Maraganore
0.2637 %
450,156 0.2637 % 1 M $
Darin Weber
0.2356 %
402,283 0.2356 % 1 M $
Todd Girolamo
0.1440 %
245,785 0.1440 % 666 077 $

Company contact information

ProKidney Corp.

2000 Frontis Plaza Boulevard Suite 250

27103, Winston-Salem

+

http://www.prokidney.com
address ProKidney Corp.(PROK)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
3.7 USD
Average target price
4.4 USD
Spread / Average Target
+18.92%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PROKIDNEY CORP. Stock ProKidney Corp.
+120.22% 248M
MODERNA, INC. Stock Moderna, Inc.
+44.48% 54.04B
LONZA GROUP AG Stock Lonza Group AG
+43.57% 41.96B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.86% 41.92B
CELLTRION, INC. Stock Celltrion, Inc.
-7.59% 28.35B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.30% 26.35B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.83% 19B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+7.15% 13B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.40% 12.28B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.15% 12.19B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PROK Stock
  4. Company ProKidney Corp.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW